Podcasts about Chemotherapy

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

[01:03:01 – 01:04:09] — Outrage Over Unilateral Iran Strikes Hosts express shock and anger at Trump's decision to bomb Iran without congressional approval, predicting escalation and criticizing the move as instigative and unconstitutional.[01:04:11 – 01:08:06] — Strait of Hormuz Closure Threat and Economic Fallout Discussion centers on Iran's threat to close the Strait of Hormuz, highlighting the potential for oil price spikes and global economic disruption due to regional instability.[01:14:53 – 01:18:11] — Critique of Zionism's Influence on U.S. Christians Criticism is leveled at the influence of Zionism within American churches, claiming theological manipulation has led to uncritical support for Israel and military aggression.[01:33:12 – 01:35:06] — China Condemns U.S. Strike and Calls for Restraint China issues an official statement condemning U.S. strikes on Iran, urging all parties to de-escalate and uphold international law and nuclear safeguards.[01:36:42 – 01:39:03] — Russia Compares Iran Strike to Iraq Invasion Lies Russia denounces U.S. attacks as violating international law, likening them to the fabricated justifications for the Iraq War and warning of global nuclear consequences.[01:52:25 – 01:53:20] — Tel Aviv Thanks U.S. for Bombing Iran A clip from Tel Aviv shows public support for U.S. military actions, prompting sharp criticism of American complicity in destruction across the region.[02:02:03 – 02:04:14] — Church Shooting Sparks Push for Armed Congregations Following a church shooting in Michigan, Polk County's sheriff urges all houses of worship to adopt active shooter response plans and bolster security, reigniting debate on arming congregants.[02:05:00 – 02:13:04] — Critique of Chemotherapy and Praise for Alternative Cancer Therapies A personal account of loss is used to critique standard cancer treatments while promoting the Templeton Wellness Foundation and manuka honey as viable natural alternatives.[02:14:01 – 02:15:53] — Fasting, EMFs, and Environmental Cancer Triggers Highlights the role of metabolic health, EMF exposure, and nutrient-depleted food in rising cancer rates, with pets cited as early warning indicators due to increased tumor diagnoses.[02:22:20 – 02:26:20] — Ivermectin and Fenbendazole as Cancer Protocols Cites doctors promoting dewormers like ivermectin and fenbendazole for cancer treatment, warns against low-quality online sources, and suggests a Canadian supplier as more trustworthy.[02:37:01 – 02:41:41] — B-17, Apricot Seeds, and Cancer Suppression Discusses historical suppression of B-17/laetrile as a cancer treatment, citing G. Edward Griffin's advocacy and promoting apricot seeds as daily preventative immune support.[02:41:43 – 02:45:16] — Glyphosate, Chlorine Dioxide, and Toxic Synergy Condemns Monsanto/Bayer for seeking immunity from glyphosate liability and promotes chlorine dioxide as a controversial but potentially effective method for detoxifying glyphosate from the body.[02:58:54 – 03:15:47] — Grace Schara Trial Recap: Alleged Hospital Negligence and End-of-Life Protocols Details the lawsuit involving the death of Grace Schara, a disabled patient allegedly given unauthorized sedatives and a DNR without family consent, raising broader concerns over hospital protocols during COVID.[03:16:01 – 03:21:45] — Suspicious Death of AI Whistleblower Suchir Balaji Examines inconsistencies in the reported suicide of a former OpenAI employee who had exposed copyright violations and criticized leadership, including forensic anomalies and surveillance failures.[03:24:01 – 03:32:13] — Dangers of AI: Surveillance, Tyranny, and Societal Dependence A wide-ranging discussion highlights AI's integration into daily life, citing loss of privacy, data abuse, blackmail potential, and fears of centralized control over human behavior and services.[03:32:15 – 03:37:24] — Creative Destruction: AI's Threat to Art, Work, and Human Connection Critiques the replacement of human-created art and labor with AI-generated outputs, lamenting the erosion of creativity, spiritual meaning, and the intrinsic joy found in skill-building.[03:47:24 – 03:55:28] — Economic Collapse Forecast and Artificial Recovery Illusions Explains how artificial stock market inflation masks broader economic collapse, blaming monetary policy and war for destabilizing the dollar and projecting a future of bartering and hardship. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

[01:03:01 – 01:04:09] — Outrage Over Unilateral Iran Strikes Hosts express shock and anger at Trump's decision to bomb Iran without congressional approval, predicting escalation and criticizing the move as instigative and unconstitutional.[01:04:11 – 01:08:06] — Strait of Hormuz Closure Threat and Economic Fallout Discussion centers on Iran's threat to close the Strait of Hormuz, highlighting the potential for oil price spikes and global economic disruption due to regional instability.[01:14:53 – 01:18:11] — Critique of Zionism's Influence on U.S. Christians Criticism is leveled at the influence of Zionism within American churches, claiming theological manipulation has led to uncritical support for Israel and military aggression.[01:33:12 – 01:35:06] — China Condemns U.S. Strike and Calls for Restraint China issues an official statement condemning U.S. strikes on Iran, urging all parties to de-escalate and uphold international law and nuclear safeguards.[01:36:42 – 01:39:03] — Russia Compares Iran Strike to Iraq Invasion Lies Russia denounces U.S. attacks as violating international law, likening them to the fabricated justifications for the Iraq War and warning of global nuclear consequences.[01:52:25 – 01:53:20] — Tel Aviv Thanks U.S. for Bombing Iran A clip from Tel Aviv shows public support for U.S. military actions, prompting sharp criticism of American complicity in destruction across the region.[02:02:03 – 02:04:14] — Church Shooting Sparks Push for Armed Congregations Following a church shooting in Michigan, Polk County's sheriff urges all houses of worship to adopt active shooter response plans and bolster security, reigniting debate on arming congregants.[02:05:00 – 02:13:04] — Critique of Chemotherapy and Praise for Alternative Cancer Therapies A personal account of loss is used to critique standard cancer treatments while promoting the Templeton Wellness Foundation and manuka honey as viable natural alternatives.[02:14:01 – 02:15:53] — Fasting, EMFs, and Environmental Cancer Triggers Highlights the role of metabolic health, EMF exposure, and nutrient-depleted food in rising cancer rates, with pets cited as early warning indicators due to increased tumor diagnoses.[02:22:20 – 02:26:20] — Ivermectin and Fenbendazole as Cancer Protocols Cites doctors promoting dewormers like ivermectin and fenbendazole for cancer treatment, warns against low-quality online sources, and suggests a Canadian supplier as more trustworthy.[02:37:01 – 02:41:41] — B-17, Apricot Seeds, and Cancer Suppression Discusses historical suppression of B-17/laetrile as a cancer treatment, citing G. Edward Griffin's advocacy and promoting apricot seeds as daily preventative immune support.[02:41:43 – 02:45:16] — Glyphosate, Chlorine Dioxide, and Toxic Synergy Condemns Monsanto/Bayer for seeking immunity from glyphosate liability and promotes chlorine dioxide as a controversial but potentially effective method for detoxifying glyphosate from the body.[02:58:54 – 03:15:47] — Grace Schara Trial Recap: Alleged Hospital Negligence and End-of-Life Protocols Details the lawsuit involving the death of Grace Schara, a disabled patient allegedly given unauthorized sedatives and a DNR without family consent, raising broader concerns over hospital protocols during COVID.[03:16:01 – 03:21:45] — Suspicious Death of AI Whistleblower Suchir Balaji Examines inconsistencies in the reported suicide of a former OpenAI employee who had exposed copyright violations and criticized leadership, including forensic anomalies and surveillance failures.[03:24:01 – 03:32:13] — Dangers of AI: Surveillance, Tyranny, and Societal Dependence A wide-ranging discussion highlights AI's integration into daily life, citing loss of privacy, data abuse, blackmail potential, and fears of centralized control over human behavior and services.[03:32:15 – 03:37:24] — Creative Destruction: AI's Threat to Art, Work, and Human Connection Critiques the replacement of human-created art and labor with AI-generated outputs, lamenting the erosion of creativity, spiritual meaning, and the intrinsic joy found in skill-building.[03:47:24 – 03:55:28] — Economic Collapse Forecast and Artificial Recovery Illusions Explains how artificial stock market inflation masks broader economic collapse, blaming monetary policy and war for destabilizing the dollar and projecting a future of bartering and hardship. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

When your doctor says you need “cancer treatment,” do you know what that actually means?Most people immediately think of chemotherapy. But if you or someone you love is facing a cancer diagnosis, understanding the full range of treatment options could be the difference between feeling overwhelmed and feeling empowered.Dr. Katie Deming sits down with Dr. Jason Konner, a medical oncologist at Memorial Sloan Kettering Cancer Center, to break down the three main types of systemic cancer treatment used today: chemotherapy, targeted therapies, and immunotherapies.Chapters:03:43 – Three Main Types of Cancer Treatment16:34 – Why First-Line Therapies Matter20:48 – Combining Holistic and Conventional Care31:23 – Essential Questions to Ask Your Oncologist43:42 – When and Why to Seek a Second OpinionDr. Konnor shares the insider perspective on second opinions, what those complex drug names really mean, and how to build the kind of relationship with your medical team that leads to better outcomes.You'll learn how some patients unknowingly sabotage their own care and what questions can instantly make you a more informed patient. Listen and learn how to walk into any oncologist's office with confidence, ask the right questions, and truly understand your options.Don't let medical jargon and complex choices keep you in the dark when clear thinking matters most.Reserve Your Spot for the June PSYCH-K® Online Workshop: https://www.katiedeming.com/psych-k-june-2025 Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/ Work with Dr. Katie: www.katiedeming.comEmail: INFO@KATIEDEMING.COM 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

How do the experts balance organ preservation, oncologic control, and emerging therapies in both localized and metastatic cases of penile cancer? This episode of BackTable Tumor Board focuses on penile cancer diagnosis and treatment, featuring urologic oncologist Dr. Charles Peyton (UAB), radiation oncologist Dr. Juanita Crook (UBC), and medical oncologist Dr. Andrea Apolo (NCI). --- This podcast is supported by:Ferring Pharmaceuticals --- SYNPOSIS This session covers case studies ranging from localized to advanced penile cancer, diagnostic practices, imaging preferences (MRI vs. CT), and treatment options, including surgery, brachytherapy, chemoradiation, and neoadjuvant chemotherapy. The multidisciplinary team highlights the complexities of treating this rare cancer, underscores the importance of physical exams, and stresses the necessity of personalized treatment plans. They also delve into the challenges of managing metastatic stages, potential salvage therapies, and the importance of clinical trials in enhancing treatment efficacy. The doctors also emphasize the potential of immunotherapy and chemotherapy combinations for metastatic disease. --- TIMESTAMPS 00:00 - Introduction02:23 - Imaging Preferences03:29 - Biopsy vs Immediate Surgery06:04 - Lymph Node Dissection vs Radiation13:48 - Brachytherapy Techniques and Case Study23:21 - Challenges in Advanced Penile Cancer27:03 - Chemotherapy and Chemoradiation30:15 - InPACT Trial37:12 - Salvage Therapies and Exploring New Treatment Frontiers44:25 - Support and Awareness for Penile Cancer51:29 - Final Thoughts --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

  Hello, and welcome to episode 175 of the Childless Not by Choice Podcast. My name is Civilla Morgan. My mission is to recognize and speak to childless women and men not by choice worldwide, reminding us that we can live joyful, relevant, and fulfilled lives, childless by choice.   Whether you have children or not, thank you for tuning in!     What is today's show about? Father's Day and Men's Health   Thank you, Patreon contributors: I would like to thank my Patreon contributors, who support the platform every month.    Your contributions help me pay my podcast producer, my podcast host, Zoom, where I interview most of my guests, and other expenses. Thank you very much!        If you are not yet a Patron, visit patreon.com/childlessnotbychoice to set up your monthly contribution. No matter your giving level, I have a gift for you!   If you prefer to give via PayPal, you can find me there at booksbycivillamorgan@gmail.com.  Your contributions to the platform are greatly appreciated! Thank you!   https://www.patreon.com/Childlessnotbychoice   Questions or comments? Contact me at:   Email: Info@civillamorgan.com                                                  Or   Visit the website at www.childlessnotbychoice.net, look to the left on the home screen, and click on the link below the telephone to leave me an up to 90-second voicemail. Body of episode: FATHER'S DAY  MEN'S HEALTH  So, well before President Biden's prostate cancer diagnosis, I had planned on discussing men's health for this year's Father's Day episode. In particular, I wanted to discuss causes of male childlessness, such as Azoospermia.  I've decided to put links in the show notes in regards to Azoospermia. Please check out the links for further information.  The basic definition of Azoospermia per The Cleveland Clinic website is:   ‘Azoospermia means there's no sperm in your ejaculate. Its causes include a blockage along the reproductive tract, hormonal problems, ejaculation problems or issues with testicular structure or function. Many causes are treatable. For other causes, it may be possible to retrieve live sperm to be used in assisted reproductive techniques like IVF.‘    As I think back through my episodes, I don't believe I've ever discussed men's health, or medical reasons men may be childless.  We've discussed fibroids, PCOS, endometriosis, adenomyosis, miscarriage, running out of time, aka the biological clock, MRKH, etc.  But I've never gone into much detail regarding issues surrounding the causes of childlessness in men.    I have had the great opportunity to interview several men about their experiences with childlessness, including how they have dealt with it. I will put links in the show notes on interviews I have conducted over the years with these wonderful men. Be sure to take a listen!    I also believe male childlessness is not as openly discussed as female childlessness because men and their spouses may find the issue embarrassing, shocking to their ego in a different way than a woman may feel about her childlessness, or maybe in much the same way.  In either case, there can be emotional and mental pain.    Some of the things that can cause infertility in men include:   AI Overview Male infertility can be caused by a variety of factors, including problems with sperm production or quality, hormonal imbalances, genetic disorders, infections, and environmental factors. Additionally, lifestyle choices like smoking, excessive alcohol consumption, and certain drug use can also contribute to infertility.  Here's a more detailed look at some of the key causes: 1. Sperm Problems: Low sperm count (oligospermia): A low number of sperm in the ejaculate. Absent sperm (azoospermia): No sperm in the ejaculate. Poor sperm motility: Sperm are unable to swim properly. Abnormal sperm morphology: Sperm are abnormally shaped, making it difficult for them to fertilize an egg.  2. Hormonal Imbalances:  Reduced testosterone: Low levels of testosterone can affect sperm production.  Hyperprolactinemia: Elevated levels of prolactin can interfere with sperm production.  Hormonal disorders affecting the pituitary gland or hypothalamus: These glands regulate hormone production.  3. Genetic Disorders: Klinefelter syndrome: A genetic condition affecting males. Cystic fibrosis: A genetic disorder that can cause blocked reproductive ducts. Myotonic dystrophy: A genetic disorder that can affect sperm production.  4. Infections and Inflammation: Epididymitis: Inflammation of the epididymis, the tube that carries sperm from the testicles.  Orchitis: Inflammation of the testicles.  STIs: Sexually transmitted infections like gonorrhea or chlamydia can cause inflammation and damage to the reproductive organs.  5. Environmental and Lifestyle Factors: Smoking: Smoking can reduce sperm count and quality.  Alcohol consumption: Excessive alcohol use can lower testosterone levels and affect sperm production.  Certain drug use: Anabolic steroids and other drugs can negatively impact sperm production.  Exposure to toxins or chemicals: Exposure to certain toxins, like pesticides, can affect fertility.  Obesity: Being overweight or obese can impact sperm quality.  6. Medical Conditions: Diabetes: Diabetes can affect sperm production and quality. Kidney failure: Kidney failure can also impact sperm production. Cystic fibrosis: A genetic disorder that can cause blocked reproductive ducts. Autoimmune diseases: Some autoimmune diseases can attack sperm.  7. Other Factors: Varicocele: Enlarged veins in the scrotum, which can raise testicular temperature and affect sperm production.  Testicular trauma: Injury to the testicles can damage sperm production.  Previous cancer treatment: Chemotherapy and radiation therapy can affect sperm production.  Undescended testicles: Testicles that don't descend into the scrotum.  Blockages or absences of tubes: Blockages in the reproductive tract can prevent sperm from being released.  This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more Whether you have children or not, your health is important. Be sure to go to all of your check-ups, especially if there is a family history of health issues. Get checked, don't wait.   Be OK with advocating for yourself. The healthcare industry may say no, you are too young for a particular test. But if you want that test, be insistent. Keep in mind that if your insurance does not cover the test because you are not of a certain age or whatever their parameters are, you may have to pay out of pocket.   Happy Father's Day to all the wonderful men out there who do the work of raising great people for this world.  Happy Father's Day to those of you who did not birth children, but are contributing to a child's life in beautiful and lasting ways.         Research links:   https://my.clevelandclinic.org/health/diseases/15441-azoospermia Articles/links of interest: https://ifstudies.org/blog/pronatalism-is-not-popular-yet Episode links to conversations with men: https://childlessnotbychoice.net/episode-143-the-things-men-talk-about-my-conversation-with-dr-robin-hadley/ https://childlessnotbychoice.net/episode-116-my-conversation-with-dave-jackson/ https://childlessnotbychoice.net/episode-141-downriver-nomad-my-conversation-with-rob-hutchings/ https://childlessnotbychoice.net/episode-130-about-fathers-day-and-childlessness/ https://childlessnotbychoice.net/episode-57-men-men-men-men-3/ My contact information: Website: www.childlessnotbychoice.net and www.civillamorgan.com Facebook: booksbycivillamorgan Instagram: @joyandrelevance Pinterest: Civilla M. Morgan, MSM LinkedIn: Civilla Morgan, MSM  

Episode 367: Pharmacology 101: PARP Inhibitors “We know that in cells that are proliferating very quickly, including cancer cells, single-strand DNA breaks are very common. When that happens, these breaks are often repaired by the PARP enzyme, and the cells can continue their replication process. If we block PARP, that repair cannot happen. So in blocking that, these single-strand breaks then lead to double-strand breaks, which ultimately is leading to cell apoptosis,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the PARP inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 13, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the use of PARP inhibitors in cancer care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 232: Managing Fatigue During PARP Inhibitor Maintenance Therapy Episode 227: Biomarker Testing, PARP Inhibitors, and Oral Adherence During Ovarian Cancer Maintenance Therapy ONS Voice articles: PARP Inhibitors and Ovarian Cancer Genomics May Trick PARP Inhibitors to Treat More Cancers Oncology Drug Reference Sheet: Niraparib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing articles: PARP Inhibition: Genomics-Informed Care for Patients With Malignancies Driven by BRCA1/BRCA2 Pathogenic Variants Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers Oncology Nursing Forum article: Familiarity and Perceptions of Ovarian Cancer Biomarker Testing and Targeted Therapy: A Survey of Oncology Nurses in the United States Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Biomarker Database ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The big toxicities here to watch for are primarily hematologic toxicities. It is one of those targeted therapies that does affect blood cell counts. So I'd say the blood cell count that is most commonly affected here is the hemoglobin. So, anemia very frequent complication that we see, probably a little bit more with olaparib compared with other drugs, but we see it as a class side effect. And we can also see neutropenia and thrombocytopenia with these agents, probably a little bit more with niraparib versus the others, but again, you can see it across all of these drugs.” TS 8:16 “We mentioned that rare risk of MDS and AML. This isn't a particularly scary thing if you talk to patients about it. Because of the rarity that we see this, it isn't something that we need to overemphasize, but I think careful monitoring of blood counts in is stressing the importance of that and early intervention here is very important.” TS 16:55 “This is a collaborative effort. And because of the home administration here, these patients do need to be followed very closely. So we are not laying eyes on them usually with the frequency that we do when we have patients actually coming into our infusion centers for treatments—so making sure that there is a plan for regular follow-up with these patients to ensure that they're getting that lab work done, that that's being looked at closely, that we're adjusting the dose if we need to based on that lab work, that we are managing the patient's fatigue. Again, that potentially dose reductions may be needed if patients are having that extreme fatigue.” TS 19:34 “I think one of those [misconceptions] could be that they're only effective in patients that have that BRCA1/2 mutation. And again, remember here that there is some data in particular disease states that we can use them and that they work in the absence of those mutations.” TS 25:12

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textPermanent Chemotherapy induced Hair loss ~ What you're not being told Shirley Ledlie was diagnosed with invasive breast cancer in 2005. She had a lumpectomy and node biopsy, and was told it had spread but the node was encapsulated. She had radiotherapy and chemotherapy with Taxoter. After her treatment, she noticed that her hair was not growing back. Her oncologist contacted the drug company, and they were aware that the treatment could cause permanent hair loss.It was then that she found out about PCIA. She has not had no hair for 20 years, and has a daily reminder of her cancer and her treatment.We discuss her story, and how permanent hair loss from Taxoter could be a lot more common than reported, and could be as high as 20-30%.Connect With Shirley:InstagramBookWebsite Hair & Scalp Salon Specialist course Support the showConnect with Hair therapy: Facebook Instagram Twitter Clubhouse- @Hair.Therapy Donate towards the podcast Start your own podcastHair & Scalp Salon Specialist Course ~ Book now to become an expert!

Keeping the Prostate healthy is important as men age.  Prostate Cancer is the #1 Cancer in Men, which includes "almost all men over the age of 80".  In this episode, you'll discover:—How keeping your Testosterone levels up can help prevent Prostate Cancer.  And why Dr. Prather believes men don't "completely function well" outside of Prostate numbers in the 800-900 range. —The Benign Prostatic Hypertrophy (BPH) condition that creates an enlargement of the Prostate and is caused by Estrogen dominance. —The reason Dr. Prather was not surprised to hear that former President Joe Biden had Prostate Cancer.  And why he would not be surprised if President Donald Trump has it, too. —Why Diet, particularly increased Fiber, and Exercise are so important for Prostate Health.  And why it's important to eliminate toxins like heavy metals, infections, and parasites that can kick off Cancer in the body.—How a Native American herbal formula first developed by Hiawatha is still used by Dr. Prather for his patients to help detox the body.  And why Dr. Prather says that it's something "almost everyone who has Cancer should be taking".—The Vitamins, Minerals, Herbals, and Homeopathics that are most helpful for Prostate health and for lowering side-effects from Chemotherapy.  And how the Prostate contains the highest concentration of Zinc in the human body and is "critical" for Prostate health.—Why Dr. Prather predicts this generation of young men will have increased rates of Prostate Cancer due to Marijuana use. —The instantaneous relief Acupuncture provides for those suffering from Prostatitis.  And why you shouldn't be afraid of where Dr. Prather puts the needles! —The amazing story of a terminal Prostate Cancer patient sent by his oncologist to Dr. Prather for pain relief through Acupuncture.  And why the oncologist called to ask what Dr. Prather was doing to the patient after seeing the patient's PSA numbers plummet. —How just preventing a patient from becoming Anemic during Cancer treatment can increase their survival chances by 50%.  And how keeping the Liver clean during Cancer treatment can increase their chance of survival by another 25%.http://www.TheVoiceOfHealthRadio.com

      Guy Nakoa has survived two diagnoses of Stage IV breast cancer.  He initially felt a lump in his breast while showering in 2000.  Because it wasn't causing him and because he didn't think could not get a type of cancer associated with women, I went more than a decade before he chose to have the lump checked out.  In 2014, he sought medical attention, he was diagnosed and in 2016, he had the lump removed; but in 2020, the cancer returned.  He was hoping it could be removed with chemotherapy and radiation treatment, but over his initial objection, he agreed to a mastectomy of his left breast in 2024.  For the rest of his life, he will need to be on two medications, ibrance and letrozole.  Guy says from time to time he experiences fatigue but is very happy to be alive.   Guy Nakoa is from Wailuku on the island of Maui in Hawaii, but he has worked all over the world as a chef.  He was on a job in Alaska in 2000, when while taking a shower, he was shocked to feel a lump in his left breast.  Guy didn't tell anyone about it because it wasn't causing him any pain, and he felt too embarrassed to admit he may have a type of cancer that is generally associated with women.    He finally decided to have the lump examined in 2014.  His doctor didn't seem to think there was anything cancerous and told Guy not to worry about it.  Guy was misdiagnosed and he believes that, like he was, his doctor might have had difficulty connecting the lump with cancer because Guy is male.  Guy went to another doctor, and in 2016, he underwent a biopsy, which revealed he had breast cancer.    Guy Nakoa had the lump removed in 2016.  He underwent a chemotherapy regimen in 2017 and again in 2018.  He says he lost his sense of taste, his anxiety level went “through the roof” and he had a tough time getting to sleep.   The surgery was a success, but in 2020, the cancer returned.  Guy wanted to again treat it with chemotherapy and radiation, but his doctor urged him to get the breast removed.  Guy eventually relented and the mastectomy took place in 2024.   Guy says these days, he can do just about anything he could do before he first felt the lump, but fatigue sometimes sets in, in a way it didn't prior to his diagnosis.  By way of advice, he is quite adamant that, regardless of what seems irregular, if you notice something, anything abnormal about your health, to immediately seek medical attention.   Additional Resources:   Support Groups:   The Male Breast Cancer Global Alliance  https://www.mbcglobalalliance.org   Man Up To Cancer  https://www.manuptocancer.org   HIS Breast Cancer Awareness  https://www.hisbreastcancer.org      

Download the Cancer Metabolic Tracker hereCheck out the Total Gut Restore courseWebsite with all the things mentionedExploring Cancer as an Adaptation: Natural Approaches and Key Questions AnsweredIn this episode, the host delves into the concept of cancer as an adaptation rather than a disease, continuing from a previous discussion. The episode answers five common questions about cancer treatment: natural support for tumor shrinkage during chemotherapy, whether chemotherapy can cause more cancer, the true meaning of 'cure', the potential role of parasites in cancer, and the impact of pesticides on cancer risk. The host emphasizes the importance of an integrative approach, including fasting, optimal timing of chemotherapy, immune support, diet, and maintaining a non-hospitable internal terrain for cancer growth. The discussion also covers the controversy around chemotherapy, the importance of gut health, and the relevance of detoxification and antioxidants in cancer management.00:00 Introduction and Overview00:31 Addressing Common Cancer Questions03:37 Natural Support for Tumor Shrinkage14:56 Chemotherapy and Secondary Cancer Risks18:28 Understanding the Concept of 'Cure'23:42 Parasites and Cancer Connection29:50 Impact of Pesticides on Cancer Risk39:12 Conclusion and Final Thoughts

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Routine checkups aren't supposed to flip your world upside down. But for Korrie Medina, they did. In this episode, Lyndsay Soprano sits down with Korrie to talk about what it means to keep living your life while battling cancer.Korrie opens up about the shock of her diagnosis, the rollercoaster of treatments—chemo, radiation, brachytherapy—and the way cancer doesn't just touch your body, but everything: your mind, your relationships, your career. Lyndsay shares her own story too—what it's like to go through the medical system, the emotional fallout, and how women are so often expected to just keep going no matter how brutal it gets.They talk about the messiness of it all—how cancer can change your life in a heartbeat, how asking for help feels like a risk, and how it's easy to lose yourself in the chaos. But they also talk about strength: how to hold on to joy, to find moments of light, and to keep moving forward even when you're running on fumes.This episode is real, raw, and a reminder that no matter what you're going through, you're allowed to take up space and put yourself first.Find Korrie Medina Online Here:Instagram: @korrieanneFacebook: Korrie MedinaFind The Pain Game Podcast Online Here:Website: thepaingamepodcast.comInstagram: @thepaingamepodcastFacebook: The Pain Game PodcastLinkedIn: Lyndsay SopranoYouTube: The Pain Game PodcastEpisode Highlights:(00:00) Introduction to Chronic Pain and Trauma(03:19) Cervical Cancer Diagnosis Journey(04:07) Understanding Cancer Staging and Treatment Options(10:08) The Hybrid Approach to Healing(12:33) Chemotherapy Experience and Its Effects(18:12) Emergency Surgery and Its Complications(23:27) The Importance of Mindset in Healing(25:19) Embracing Happiness Amidst Struggles(26:18) The Mind-Body-Soul Connection(27:39) Navigating the Aftermath of Treatment(28:38) Understanding Brachytherapy(30:36) The Brutality of Medical Procedures(31:32) The Aftereffects of Radiation(33:45) The Reality of Menopause(35:45) Hormonal Imbalance and Mental Health(37:40) Reaching a Breaking Point(39:09) Seeking Help in Crisis(41:31) Reflections from the Psych Ward(43:40) The Importance of Self-Care(45:49) Empowering Women Through Adversity

BUFFALO, NY - June 3, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 19, 2025, titled “PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling." In this study, led by first author Reem Ali and corresponding author Dindial Ramotar from Hamad Bin Khalifa University in Qatar, researchers discovered that a protein called PRDX1 helps maintain the stability of ATM, a key protein involved in repairing damaged DNA, especially when cells are under stress from arsenite exposure. The study found that without PRDX1, cells lose their ability to repair DNA and become more sensitive to chemotherapy. This finding suggests that targeting PRDX1 could improve the success of some cancer treatments. PRDX1 is already known for its role in protecting cells from oxidative damage, but this study shows it also plays a role in the DNA repair process. ATM is an essential protein that detects breaks in DNA and starts the repair process. When PRDX1 is missing, ATM is rapidly lost, especially when cells are exposed to arsenite, a toxic substance found in the environment. Without ATM, the DNA repair system fails, leaving cells more vulnerable to damage. By using both human cell lines and clinical samples from ovarian cancer patients, the team showed that high levels of PRDX1, along with ATM and MRE11 (another DNA repair protein), were linked to tumors' aggressive features and lower patient survival rates. This pattern suggests that tumors with high PRDX1 may resist chemotherapy by increasing their DNA repair capacity. On the other hand, removing PRDX1 weakened the repair system and made cancer cells more responsive to DNA-damaging platinum drugs. The study also showed that combining low doses of arsenite with drugs that either block ATM or damage DNA caused a much higher rate of cancer cell death in cells that lacked PRDX1. These results suggest a new treatment approach: lowering PRDX1 levels to make cancer cells more sensitive to DNA-damaging platinum therapies already in use. This highlights PRDX1 not only as a protector of cell function but also as a potential weak point in cancer cells. “As such, we propose that small molecule inhibitors of PRDX1, or single nucleotide polymorphisms that compromise PRDX1 function, in combination with low doses of arsenite can be exploited to treat chemo-resistant tumours.” These findings open the door for the use of PRDX1 as a biomarker to predict treatment response and as a promising target for new combination therapies. For patients with ovarian cancer and potentially other tumors, adjusting PRDX1 levels may help overcome drug resistance and improve outcomes. DOI - https://doi.org/10.18632/oncotarget.28720 Correspondence to: Dindial Ramotar - dramotar@hbku.edu.qa Video short - https://www.youtube.com/watch?v=suOhF7mPlNQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28720 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, redox signaling, homologous recombination, protein interaction, cell cycle, protein modification To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

EXCLUSIVE: 'Baywatch' Pin-Up Nicole Eggert's Brutal Cancer Fight Comeback Revealed in Full - Including Mastectomy, Chemotherapy and Radiation TherapyAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

JCO Editorial Fellow Dr. Peter Li and JCO Associate Editor Dr. Andrew Ko discuss the ASCO 25 Simultaneous Publication paper "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Peter Li: Hello, everyone, and welcome to our 2025 ASCO Annual Meeting Series where we cover some of the top JCO papers published simultaneously with their abstract presentation at this year's meeting. I'm your host, Dr. Peter Li, JCO Editorial Fellow, and I'm joined by Dr. Andrew Ko, JCO Associate Editor, to discuss the Journal of Clinical Oncology article and abstract presentation "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Now, let's start off with the relevance of this article. Andrew, can you please explain this to our listeners? Dr. Andrew Ko: Sure. Thanks, Peter. So, this was a very large international study evaluating the combination of lenvatinib and pembrolizumab. And just for context, that combination has been approved for use in other solid tumor types. It's FDA approved for renal cell carcinoma, for example, and endometrial carcinoma. But this study was looking specifically at this combination together with a chemotherapy backbone - so either FOLFOX or CAPOX - and comparing that to what at the time was a standard of care, which was just standard chemotherapy by itself. So, this very large study was intending to look at this particular novel combination. And we can get into some of the nuances of this study because the way that the experimental, the combination arm, was designed was perhaps a little bit more on the unusual side and led to maybe some imbalance in terms of how we think about the respective arms. Dr. Peter Li: Okay. We can definitely talk more about that as we go on. So, what are some of the key results of this study, and how do you think this will impact practice in the future? Dr. Andrew Ko: That's a good question. Technically, it was not a positive study. Well, it was positive in the sense that the co-primary endpoints - which included both progression-free survival and overall survival - so, progression-free survival, it did technically meet its endpoint, both in terms of the overall population and the preplanned subgroup analysis of patients who had a PD-L1 CPS of greater than or equal to 1. So, there was a PFS benefit with the experimental combination - the lenvatinib, pembrolizumab, plus chemotherapy - compared to chemotherapy alone. I will say the benefit was on the more modest side. So, if you even look at the medians, it was not a marked difference. If you look at the hazard ratios, they did meet statistical significance. On the other hand, this did not translate into a benefit for overall survival. So, when you ask, "Well, is this going to inform practice?" I'd have to say no. It highlights, I think, that JCO does want to publish articles that aren't necessarily going to be practice-changing, but that I think offer a lot of insights into trial design and important aspects of investigating novel treatments, even if they don't end up moving the needle in routine clinical practice. Dr. Peter Li: I totally agree with you. I mean, it was significant in terms of progression-free survival, but again, not clinically significant. And then overall survival, the interventional arm actually appeared to do slightly worse overall. Can you make some comments on the strengths and the weaknesses of this study, and where do you see us going from here? Dr. Andrew Ko: So, I think a couple of things worth highlighting in this study, very well designed, more than 800 patients in total. So, first of all, as I mentioned at the beginning, the combination was a little bit unique in terms of patients enrolled to the experimental arm got the combination of lenvatinib, pembrolizumab, together with chemotherapy for a very finite duration. So, that period of chemotherapy they received was only three months. And per protocol, patients then just segued to, quote unquote “maintenance treatment” with just the lenvatinib and pembrolizumab combination. Whereas patients on the control arm, meaning chemotherapy alone, would continue chemotherapy basically in perpetuity until their disease progressed or intolerable toxicity. So, there really was an imbalance in terms of, if you think that chemotherapy or continuing chemotherapy beyond that initial three-month period of time may be significant, that could have had some impact on the robustness or the efficacy of the experimental arm. There were some other aspects in terms of perhaps some differences in the rates of post-progression treatment, in other words, patients going on to receive second-line treatment. I think the other very relevant aspect, Peter, in this study was that the control arm - and no fault of the investigators - but the control arm at the time the study was ongoing just consisted of chemotherapy, FOLFOX CAPOX, by itself, without an immune checkpoint inhibitor, right? And we clearly know, based on results of several large phase III studies, and it's now in standard clinical practice, that we routinely use chemotherapy plus an immune checkpoint inhibitor. Certainly for patients with CPS PD-1/PD-L1 scores that are, well, you could argue greater than 1, or perhaps greater than 5 or 10. But the point being that the control arm of the study probably doesn't reflect what is currently used in clinical practice. And that's just always a challenge in clinical trial design, right? That when a study is designed and when it rolls out, you're always at risk in a rapidly changing and moving field that the standard of care may evolve during the lifetime of that particular trial, which is what I think you see in LEAP-015. Dr. Peter Li: Totally understand. And the survival we see from this study is also roughly similar to the combination of immuno-chemotherapy that is the standard of care today, which is, the authors mentioned, 12 to 14 months. Thank you so much, Andrew, for your input and for speaking about the JCO article "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Join us again for the latest simultaneous publications from the 2025 ASCO Annual Meeting. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Shannon Salvador, MD, MSc, FRCSC - Advancing Frontline Endometrial Cancer Care: Translating the Latest Advances in Immunotherapy Plus Chemotherapy Regimens to Practice

After a scary and lonely battle with cancer, Val Russel, owner of the Flying Hatter, wants to use her experience to help others undergoing cancer treatment. Hats for the C Word gives cancer patients the opportunity to design a free custom hat. By Sadie Smith.  Watch this story at www.durangolocal.news/newsstories/hats-for-the-c-word  This story is sponsored by Durango Gelato, Coffee & Tea and Crystal Mart.  Support the show

Sheila Romanski is with us today after overcoming two diagnoses of breast cancer and the removal of a tumor in her left shoulder thanks to an autologous stem cell transplant.  She tells the @CancerInterviews podcast her initial of Stage 1A breast cancer in 1996 came after her doctor suggested a routine mammogram at age 36 when at the time mammograms were not performed on women that young.  Radiation treatment successfully addressed that diagnosis, but the following year, the cancer had metastasized to her shoulder.  That brought on the stem cell transplant, plus chemotherapy and more radiation.  All seemed well until 2008 when the breast cancer returned as Stage 4 triple negative infiltrating ductal carcinoma.  Shiela opted for a double mastectomy with reconstruction, which was followed by a second, more aggressive form of chemotherapy.  She has been pronounced NED (No Evidence of Disease), and now enjoys a healthy lifestyle, leading a non-profit that aids cancer victims.   Sheila Romanski advises everyone to do self-examinations for breast cancer.  She admits had she done so, her breast cancer would have been caught sooner.  In 1996, it was rare that 36-year-old women went in for routine mammograms, but Sheila's doctor suggested such an exam.  Thanks to that suggestion, a 2cm tumor was found.  She underwent a lumpectomy and radiation treatment.   While it appeared cancer was in her rear-view mirror, in 1997, a lump was found in her collar bone area.  That was treated with four chemotherapy treatments and autologous stem cell transplant, a procedure involved her own stem cells.  The chemo and the transplant last four months.   For Sheila, this time in her life was very challenging.  She was no only battling cancer, but she was raising four small children.  However, she says she was able to get through because of support from her friends and her church, and because attending to the needs of her kids took her mind off cancer.   Sheila's health appeared to be on the right track until 2008 when another routine mammogram revealed micro-calcifications in the same breast as her original diagnosis.  She decided a double mastectomy would be her best option. It would include a procedure called a diep flap, which involves taking skin from other parts of the body.  However, her surgeon said Sheila would have to lose twenty pounds before diep flap could be performed.  It took Shiela ten years to lose the weight and by that time, her surgeon said she no longer performed diep flap.  However, she said she could get Sheila “fixed up” and in 2021, thirteen years after mastectomy, reconstruction was complete.   Sheila Romanski has gone on to found Crystal Roses, a non-profit that seeks to aid those diagnosed with cancer.   Additional Resources:   Support Group:   Crystal Roses  https://www.crystalroseshelps.com    

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2015, Daniel Garza experienced bloating and difficulty completing a bowel movement.  A subsequent digital rectal exam revealed a mass on his sphincter, which led to a diagnosis of anal cancer.  A surgical procedure got rid of the cancer, but it also resulted in his losing half of his sphincter and the temporary presence of a fistula, a tear which was like a second anus.  He underwent a chemotherapy regimen of 5-fluorouracil, followed by radiation treatment, but another major challenge awaited Daniel, as he had to wear an ostomy bag, which he does to this day.  He deals with the bag and has continued his work as an advocate for those with HIV and anal cancer, in addition to being an actor and a comic.   Daniel Garza thought he was in good health until he was plagued by a nasty variety of symptoms.  He experienced bloating, stomach pain, bowel movement blockage and anal bleeding.  The initial conclusion of his doctor was that he had a strangulated intestine tied to a hernia he suffered years earlier.  He prescribed a number of treatments, which did no good.   Daniel went back to the doctor and went through blood tests and a CT scan.  But it was a subsequent digital rectal exam that revealed a mass on his sphincter.  That led to a biopsy and a diagnosis of squamos cell carcinoma of the anus, also known as anal cancer.   The mass was on one side of Daniel's sphincter.  Surgery removed the cancer but also removed half of his sphincter.  Next up was chemotherapy, a type known as 5-fluorouracil, then radiation treatment and time in a hyperbaric chamber.    The cancer was gone, the aforementioned fistula healed, but to dispose of the waste in his system, Daniel had to be fitted with an ostomy bag, which he eventually named Tommy.  He went through three ostomy nurses and two types of bags before he felt comfortable managing the bag.   These days, Daniel Garza says he is doing his best to make peace with Tommy.  It hasn't stopped him from continuing his life as an advocate for those dealing with HIV and anal cancer.  He also travels the world as an actor and a comic.   Additional Resources:   Support Groups:   Man Up To Cancer: https://www.manuptocancer.org   Cheeky Charity: https://www.cheekycharity.org    

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

- Broadcast News Introduction and Upcoming Segments (0:00) - AI Advancements and Their Impact on Jobs (0:45) - Breaking News: Trump-China Trade Deal and Its Implications (2:46) - Pakistan-India Cyber War and Its Potential Escalation (9:55) - Power Grid Vulnerabilities and Preparedness (13:36) - Crypto Wallets and the Importance of Self-Custody (19:04) - AI Capabilities and Their Implications for Human Jobs (25:14) - The Role of Enoch AI in Empowering Users (59:30) - The War on Human Cognition and Its Vectors (1:05:29) - Strategies for Protecting Cognitive Function (1:21:34) - Chemotherapy and Cognitive Impairment (1:21:56) - Natural Light and Sun Exposure (1:25:06) - Media and Information Warfare (1:30:33) - Societal and Behavioral Factors (1:33:37) - Defending Against Environmental Toxins (1:41:05) - Nutritional and Dietary Factors (1:47:00) - Pharmaceutical and Medical Warfare (1:49:22) - EMF Exposure and Technological Risks (1:59:51) - Information Warfare and Censorship (2:02:12) - Societal and Behavioral Factors (2:11:11) - Zionist and Chinese Strategic Moves in the Middle East (2:25:45) - Trump's Arrogance and Military Presence in Panama (2:26:04) - China's Influence and Economic Strategy in Panama (2:26:21) - Strategic Importance of the Panama Canal (2:52:23) - Strait of Hormuz and Global Energy Supply (3:06:20) - US-China Trade War and Economic Implications (3:14:03) - Anthropological Warfare and Cultural Resilience (3:14:21) - Migration and Demographic Warfare (3:22:15) - Global Economic and Political Dynamics (3:28:51) - Future Strategic Moves and Predictions (3:33:17) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Episode Summary: In the beatitudes, Jesus paints a portrait of spiritual vitality and health into which Christ's kingdom members are being transformed. But at the root of that transformation process is cutting out the cancer of sin. Such excision of sin requires both confessing it, the first beatitude, and grieving over it, the second beatitude. The combination of these two attitudes is called repentance. The problem is that Christians can be lured into a kind of shallow, incomplete repentance that is destructive. It might be compared to surgery to remove the cancerous tumor that misses part of the tumor. Paul calls it “worldly sorrow that leads to death.” In contrast, says Paul, is “godly sorrow leading to repentance.” This godly sorrow corresponds to getting all the tumor and then using chemotherapy to destroy what is microscopic and missed. This kind of sorrow is the heart attitude Jesus refers to in the second beatitude. “Blessed are those who mourn, for they shall be comforted.” It is an attitude that is exhibited by David. It is described in unmistakable detail in Psalm 51, which he wrote after being confronted with his sin of adultery with Bathsheba and murder of her husband, Uriah. It is chemotherapy for sin.For Further Prayerful Thought: How would you defend the argument that confessing our sins is not enough; we need to grieve over them.What most stood out to you about David's confession of his sin in Psalm 51?How does Jesus' claim to be the messianic suffering servant whose ministry is described in Isaiah 61 show that his mission goes beyond going to the cross so we could be forgiven for our sins? What clues in Isaiah 61 and the second beatitude point to Jesus' current work of restoration—fixing whatever was broken by sin?For the printed version of this message click here.For a summary of topics addressed by podcast series, click here.For FREE downloadable studies on men's issues click here.To make an online contribution to enable others to hear about the podcast: (Click link and scroll down to bottom left)

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications

Chemotherapy not only changes how your brain thinks, it also impacts your emotional regulation. How do you manage brain fog and chemo rage? Listen to learn about ways to harness this emotional energy and channel it in productive ways.  https://bit.ly/4iWTmpMIn this Episode:01:39 - Streaming Series Review:  Adolescence05:22 - New Jersey and Coconut Cream Pie06:23 - What Does American Medical Debt Look Like?10:17 - Chemo Rage: What it is and What Causes it17:21 - How to Cope with Chemo Rage20:34 - How to Help a Loved One with Chemo Rage24:57 - Poem, "Speak the Cancer"26:20 - OutroSupport the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

“The signaling and that binding of the MET and the HGF help, in a downstream way, lead to cell proliferation, cell motility, survival, angiogenesis, and also invasion—so all of those key cancer hallmarks. And because of it being on an epithelial cell, it's a really good marker because it's found in many, many different types of cancers, so it makes it what we call kind of a nice actionable mutation,” ONS member Marianne Davies, DNP, ACNP, AOCNP®, FAAN, senior oncology nurse practitioner at Yale Comprehensive Cancer Center in New Haven, CT, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the MET inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 9, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to MET inhibitors. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Capmatinib Oncology Drug Reference Sheet: Tepotinib Predictive and Diagnostic Biomarkers: Identifying Variants Helps Providers Tailor Cancer Surveillance Plans and Treatment Selection ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) Telephone Triage for Oncology Nurses (third edition) ONS courses: Safe Handling Basics ONS Biomarker Database ONS Huddle Cards: Monoclonal Antibodies Targeted Therapy ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets IV Chemotherapy Education Sheets Drugs@FDA To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The MET receptor was actually identified back in 1984. And it was actually identified as an oncogene in osteosarcoma. And so basically what that MET receptor does—it's a tyrosine kinase pathway, and the ligand that it attaches to is something called HGF/SF. That's hepatocyte growth factor/scatter factor. And so this MET pathway tyrosine kinase pathway is really important in tumor cell growth and migration. And it's expressed specifically on epithelial cells, so that's going to really help us in identifying how it can be a pathway for cancer treatments.” TS 1:35 “But in the particular classes, there kind of are some unique things that are with these MET inhibitors. For example, crizotinib, we found early on, causes some vision changes. Patients would report things like floaters or a little bit of blurry vision. For the capmatinib, things like elevation of amylase and lipase, fluid retention and bloating, and hypersensitivity reactions and photosensitivity.” TS 7:36 “Other things to teach for the TKI is the self-management strategies in terms of nausea management and dietary changes for the risk of peripheral edema. Having them do things like maybe doing daily weights, or at least weights every other day, and sometimes doing limb measurements so it can help us really quantify the amount of fluid retention they have. And then from a nursing perspective, meeting with these patients, is to do really good skin inspection. When people have peripheral edema, they're at risk for skin breakdown, and that can lead obviously to infection.” TS 16:06 “The biggest [misconception] is that people assume that all MET mutations are going to be equally responsive to the same targeted therapies, that all of the abnormalities are the same and react the same, and they really don't. We're really diving down and carving that pie thinner and thinner in terms of each individual MET abnormality, in terms of what drugs responds it to and what that means for patient outcomes and prognosis.” TS 25:21

In this week's episode, we'll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin. Featured Articles:Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Babesiosis and Sickle Red Blood Cells: Loss of Deformability, Heightened Osmotic fragility and Hyper-vesiculation 

On this week's episode, Dr. Cox struggles to support his best friend through Chemotherapy. In the real world, Zach and Donald are joined by Brendan Fraser! Brendan reveals his love of photography, that time he worked with Mos Def, and what it's like to be stopped by Scrubs fans nearly 20 years after his first appearance on the show. See omnystudio.com/listener for privacy information.

 How does chemotherapy work and why does it cause side effects? We answer these questions and more in this episode as we continue our series about cancer with a discussion about chemotherapy. https://bit.ly/42HvhykIn this Episode:03:31 - Travel: Rhode Island and Clam Cakes04:35 - Anna Quindlen - We Need to "Get a Life"08:45 - Chemotherapy Overview: How it works, Cycles, Port12:19 - Types of Chemotherapy Drugs15:35 - Apoptosis and Chemo Success17:04 - Side Effects of Chemotherapy18:02 - Discussion - "How Long Has Chemo Been in Use?"21:41 - Jeena R. Papaadi, "The Person in the Bed"24:51 - OutroRelated Episodes:S6E4: Understanding Cancer Treatment Options: ImmunotherapyS6E3: Understanding Cancer Treatment Options: Radiation TherapyS6E2: Understanding Cancer Treatment Options: SurgeryS5E52: Cancer Gone Wild – Learn All About MetastasisS5E45: Why Does Cancer Exist? Empower Yourself With UnderstandingS5E46: “Why Do I Have Cancer?” Kismet, Chastisement or Coincidence?S5E47: MythBusters – Cancer Edition; Clarifying Common Cancer Myths & MisconceptionsS5E48: How to Read a CT Scan Report – Learn the Sections Relevant to Your DiagnosisS5E49: Are there Miracle Cures for Cancer? With Dr. Jeanna FordS5E50: What is Meant by Cancer Staging? Learn the Language of a Cancer Diagnosis#cancer #cancertreatment #cancertreatmentoptions #chemotherapyeducation #palliativecare #cancereducation #cancerresources #sideeffects #everydayisagift #everyonediesSupport the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

In this episode, our guest Sharon, from Scotland, shares her powerful journey of overcoming stage 3 ovarian cancer. After a difficult experience with chemotherapy, Sharon turned to cannabis oil—and believes it played a key role in her survival. Now cancer-free and devoted to helping others, she opens up about the stigma, the scams, the healing, and the deeper personal transformation that followed.This is a story of fierce determination, intuitive self-advocacy, and the healing potential of plant medicine.00:38 – Introduction: Ovarian cancer stats and global impact01:52 – Sharon's first symptoms and long path to diagnosis03:02 – The moment she was told she had cancer04:46 – Mental health, grief, and personal transformation06:56 – Relationships lost and reshaped after diagnosis07:10 – Chemotherapy: side effects and regret08:39 – Finding cannabis oil and getting scammed10:29 – The importance of trusted sources and education11:12 – Taking oil before, during, and after chemo13:40 – “I'd be dead without it”—how cannabis helped her survive17:39 – Continued use of oil and current regimen19:31 – Managing chemo-induced neuropathy21:40 – Family dynamics and their view of cannabis23:12 – Survivor's guilt and a desire to help others28:01 – Nutrition, self-care, and guiding others toward options30:57 – Her advice to women newly diagnosed with ovarian cancer34:39 – Final thoughts and gratitude Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

You cannot know Jesus in any real depth unless you share in his sufferings. -------- Thank you for listening! Your support of Joni and Friends helps make this show possible.     Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org   Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

In this episode, Dr. Jake breaks down the truth about Vitamin C and chemotherapy, debunking myths and revealing how high-dose IV Vitamin C can actually enhance cancer treatment. Dr. Jake, a naturopathic medical doctor and integrative physician, shares insights on how this natural and non-toxic treatment and whether or not it actually reduces chemotherapy side effects like fatigue, nausea, and neuropathy, without compromising its effectiveness. And does it work best by integrating such protocols with conventional treatments for optimal results? Doctor Jake speaks on all of this. If you're curious about root cause solutions and integrative health strategies, Dr. Jake's got you on that! Dive into integrative healing approaches and get empowered to improve your well-being. Ready for Vitamin C infusions? Contact Dr Jake at https://integrativemedica.com#vitaminc #Chemotherapy #NaturalHealing #IntegrativeHealth

I'm a 70-year-old woman with hip arthritis. Any recommendations?A treatment on the horizon for high Lipoprotein (a)?After chemotherapy to help shrink a tumor near my husband's spine, he now has numbness and neuropathy in his legsAnother study implicates meat, and now poultry and fish, in causing cardiovascular diseaseWhat do you think of Consumer Lab's recommendations on supplements?I take CoQ10, but I just heard about PQQ. What are your thoughts?

Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness  https://www.katiedeming.com/prolonged-water-fasting/What would you do first if you received a cancer diagnosis? Dr. Katie shares why a 30-day water fast would be her first response to cancer—and why many health experts like Dr. Mark Hyman and Dr. Jason Fung agree. Dr. Deming presents six compelling reasons why prolonged water fasting creates powerful healing opportunities for cancer patients. She explains how cancer as a metabolic condition responds to fasting, why it helps detoxify the body on physical, emotional and mental levels, and how it flips the script on cancer's parasitic nature. You'll hear real examples of clients who experienced profound healing through this approach, including one whose brain tumor completely disappeared.Key Takeaways:How to shut down your cancer's fuel sourceLetting go of years of toxic buildupWhat a stronger gut means to youClarity comes when the noise inside quiets downDr. Deming transparently shares her journey from skepticism to conviction based on client outcomes she never witnessed in traditional medicine. Her honest assessment of water fasting challenges common medical assumptions while offering hope to those seeking alternatives or complementary approaches.Dr. Deming explains the science behind water fasting while acknowledging safety considerations and proper supervision. Listen and expand your understanding of what's possible when we create the right conditions for our bodies to heal themselves naturally.Send us a text with your question (include your phone number) Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatie Don't Face Cancer Alone"The 6 Pillars of Healing Cancer" workshop series provides you valuable insights and strategies to support your healing journey - Click Here to Enroll MORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/6 Pillars of Healing Cancer Workshop Series - Click Here to EnrollWork with Dr. Katie: www.katiedeming.comFollow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Take a Deeper Dive into Your Healing Journey: Dr. Katie Deming's Linkedin Here Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER:The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose...

Jill opened the show talking about her new Rebelle Rally team. Listen in for details. Tom shared some information about a not-for-profit organization that packages sundry products for patients undergoing Chemotherapy. The packages include items to help recipients deal with chemo side effects, including loss of taste, dry skin, and dehydration. You can check out Lemons of Love at lemonsoflove.org. The hosts went to discuss the Cybertruck. The polarizing Tesla pickup is no longer being accepted in trade by Tesla, a thing which will likely impact resale value. Also, Tesla has introduced a new, less expensive Cybertruck trim level, which may lure some shoppers back into showrooms. Tom noted the addition of a more affordable trim level to the GMC Sierra EV lineup. The new model lowers the cost of entry for a Sierra EV considerably. Still in the first segment, Jill and Tom talked about Jeff Bezos' new EV startup Slate Auto. The new company is gearing up to produce small, $25,000 electric pickup trucks meant to be customized by the end user. Production begins as early as late next year. In the second segment, the hosts welcome veteran auto journalist Gary Witzenburg to the show. Gary talked about a pair of articles he recently wrote, both about 2-seat Pontiacs. The first, which appeared recently in Collectible Automobile, covered the Fiero. The latter, which appeared on the Haggerty website, covered the brand's Solstice small sports car. Listen in for fascinating insights into both cars. In the last segment, Jill is subjected to Tom's “Sixty More Seconds” quiz. How did she do? Listen in. 

Editor in Chief Dr. Sue Yom hosts a discussion on the role of radiation for gallbladder cancer, as it is managed in India versus the U.S. Guests are Section Editor Dr. Michael Chuong, Vice Chair and Medical Director of Radiation Oncology at Miami Cancer Institute, and Dr. Sushma Agrawal, Professor from the Department of Radiotherapy at Sanjay Gandhi Post Graduate Institute of Medical Sciences in Lacknow, India, RACE-GB Principal Investigator, and first author of the primary trial report, A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB Study.

“It's been known for quite a while that [KRAS] is a mutation that leads to cancer development, but for really over four decades, researchers couldn't figure out a way to target it. And so, it was often considered something that was undruggable. But all of this changed recently. So about four years ago, in 2021, we had the approval of the first KRAS inhibitor. So it's specifically a KRAS G12C inhibitor known as sotorasib,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the KRAS inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 11, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to KRAS inhibitors used for cancer treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Cancer Symptom Management Basics series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: First KRAS-Targeted Therapy Receives FDA Approval for Lung Cancer Oncology Drug Reference Sheet: Adagrasib Oncology Drug Reference Sheet: Sotorasib ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS course: Safe Handling Basics ONS video: What is the role of the KRAS biomarker in NSCLC? ONS Targeted Therapy Huddle Card ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets Lumakras® (sotorasib) manufacturer website Krazati® (adagrasib) manufacturer website UpToDate Lexidrug (formerly Lexicomp) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “If we look at specifically non-small cell lung cancer, this KRAS mutation is one of the most frequently detected cancer drivers or driver mutations. It's thought that about a quarter of cases of non-small cell lung cancer have this KRAS mutation, and it's usually a specific amino acid substitution that we see in non-small cell lung cancer, so what's known as KRAS G12C mutation.” TS 2:31 “Both of these agents, sotorasib and adagrasib, have the same mechanism of action. They bind to a pocket, very specifically on the KRAS G12C protein, and they lock it in an inactive state so that it can't cause that downstream uncontrolled signaling to happen. So they're kind of shutting down the signaling, and therefore you don't get that uncontrolled cell growth and proliferation.” TS 4:27 “Another big difference to point out, and one that is often used in clinical practice to differentiate when to use these agents, is specifically adagrasib is known to have activity in patients with metastatic non-small cell lung cancer that have active brain metastases. In the clinical trial, they included patients with active brain metastases, and they found that this drug has great [central nervous system] penetration. And so it may be considered the agent of choice in patients with brain metastases.” TS 7:19 “Other considerations—I think one of the big ones—is that there are a lot of drug interactions. Just specifically calling one out that I think is pretty impactful, is sotorasib has an interaction with acid-suppressing medications. So there is the recommendation to avoid [proton pump inhibitors] and H2 antagonists in patients receiving sotorasib. They can take antacids, but you would need to space those out from their dose of sotorasib.” TS 14:14 “This needs to be a collaborative endeavor to make sure these patients are monitored appropriately. We are putting a lot of responsibility on the patients with all of this. So, again, completely administered generally in the home setting, a lot of monitoring, a lot of adverse effects, need for reporting and management—so there's a lot happening here. And it takes a team to accomplish this and to do it right. And I firmly believe that this is often a collaborative effort between our pharmacy and oncology nursing teams to make this happen. Working together to ensure outreach to patients—I think that patients are often more successful with these medications with early identification of toxicities when we're doing scheduled outreach.” TS 19:44

In this week's episode we'll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.Featured Articles:IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromesTargeting cell-surface VISTA expression on allospecific naïve T cells promotes toleranceEpcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Elena Castro joins Tom and Brian on the day after Pluvicto approval pre-chemotherapy in the US to discuss the PSMA Fore data and application in clinical practice.

“There have been many changes since the '70s that have shaped the nurse's role in administering chemo, and in supporting patients. The major change early on was the transition from that of nurses mixing chemo to that of pharmacists. Regulatory agencies like NIOSH and OSHA defined chemotherapy as hazardous drugs, and professional organizations became involved, leading to the publication of the joint ASCO and ONS Standards of Safe Handling,” ONS member Scarlott Mueller, MPH, RN, FAAN, secretary of the American Cancer Society Cancer Action Network Board and member of the Oncology Nursing Foundation Capital Campaign Cabinet, told Darcy Burbage, DNP, RN, AOCN®, CBCN®, ONS member and chair of the ONS 50th Anniversary Committee during a conversation about the evolution of chemotherapy treatment. Along with Mueller, Burbage spoke with John Hillson, DNP, NP, Mary Anderson, BSN, RN, OCN®, and Kathleen Shannon-Dorcy, PhD, RN, FAAN, about the changes in radiation, oral chemotherapy, and cellular therapy treatments they have witnessed during their careers. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: 50th anniversary series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 59: Blood and Marrow Transplant Nursing Episode 16: Navigating the Challenges of Oral Chemotherapy ONS Voice article:Safe Handling—We've Come a Long Way, Baby! ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (second edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: ONS Hematopoietic Stem Cell Transplantation™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Safe Handling Basics Oral Anticancer Medication Toolkit Oral Anticancer Medication Care Compass Patient education guides created as a collaboration between ONS, HOPA, NCODA, and the Association of Community Cancer Centers: IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Hillson: “I remember as a new grad, from back in '98, walking up to the oncology floor. We had patients with pink labels on the chart and that was the radiation oncology service. I hadn't heard of such a thing before. … I'd gone through nursing school and hospital orientation and unit orientation without ever hearing of these therapies. At the time, both the management and the union had no interest in specialist nurses, and the really weren't any books that were targeting the role. And it was very isolating and frightening. I was very glad to find ONS when I moved to the U.S. Right now, the Oncology Nursing Society Manual for Radiation Oncology, Nursing Practice, and Education, it's in its fifth edition and a sixth is underway. There's nothing else like it. Most books are very much geared towards other professions.” TS 5:34 Mueller: “We mixed our chemo in a very small medication room on the unit, under a horizontal laminar flow hood, which we later discovered should have been a vertical laminar flow hood. Initially, we did not use any personal protective equipment. I remember mixing drugs like bleomycin and getting a little spray that from the vial onto my face. And to this day, I still have a few facial blemishes from that.” TS 14:28 Anderson: “As the increasing number of these actionable mutations continue to grow, so will the number of oral anticancer medications that patients are going to be taking. And we are already seeing that there's multiple combination regimens and complex schedules that the patients have to take. So this role the oral oncolytic nurse and the nursing role, like you said, it cannot be owned by one individual or discipline. So it's not a pharmacist; the pharmacies aren't owning this. The nurses are not owning this. It takes a village.” TS 32:12 Shannon-Dorcy: Then as immunotherapy comes into the picture, we start to learn about [cytokine release syndrome]. All of a sudden, we had no concept that this was a deadly consequence. ONS was on the front lines, convening people across the country together so we could speak to the investigative work with science and find ways that we could intervene, how we can look for signs of it early on with handwriting testing.” TS 39:58

What if your skin could do more than protect you? In this thought-provoking episode of The Technology of Beauty, Dr. Grant Stevens sits down with Ryan Beal, the CEO of Dyve Biosciences, to explore how transcutaneous drug delivery is poised to reshape both the aesthetics industry and the field of oncology. With Dyve's pioneering platform, molecules once limited to injections or oral delivery are now being driven through the skin — offering a powerful new frontier in treatment possibilities.Ryan walks us through Dyve's surprising evolution from skincare applications and elite athletic performance enhancement to its most ambitious moonshots: noninvasive fat reduction and improving chemotherapy effectiveness through targeted pH modulation.This episode also takes a personal turn, as Ryan opens up about his recent battle with cancer—a diagnosis that came just months after speaking about oncology research on a previous episode. Now a survivor, Ryan shares how his company's technology played a direct role in his treatment, potentially boosting the efficacy of his own chemotherapy regimen. It's a powerful testament to the impact of innovation when professional purpose and personal experience collide.From fat-melting topicals to transdermal neurotoxins and tumor microenvironment alkalinization, Ryan Beal offers an inspiring look at how Dyve Biosciences is transforming medicine one molecule—and one patient—at a time. Don't miss this candid, cutting-edge conversation about the future of drug delivery and the deeply human stories behind biotech breakthroughs on the latest episode of The Technology of Beauty.» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/

Karen shares how a friend's breast cancer diagnosis became a powerful example of self-advocacy in action. From discovering she didn't need chemotherapy after requesting additional testing, to researching scalp cooling treatments and skin protection during radiation, this story highlights how knowledge and persistence can lead to better care. Visit our website itchyandbitchy.com to read blog posts on the many topics we have covered on the show.

“And so you have different kinds of hazards with the drugs that you're using. That means that in the past, when a lot of oncology drugs, antineoplastic drugs used to treat cancer would have been added, you may see that a lot of oncology drugs either weren't added or they're added in a different place on the list than they were in the past. That's due to some of the restructuring of the list we'll probably talk about later,” Jerald L. Ovesen, PhD, pharmacologist at the National Institute for Occupational Safety and Health (NIOSH) and Centers for Disease Control and Prevention, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the latest update to the NIOSH list of hazardous drugs.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Episode Notes   NCPD contact hours are not available for this episode.  ONS Podcast™ episodes: Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs  Episode 142: The How-To of Home Infusions Episode 68: Empowering Healthcare Workers to Handle Hazardous Drugs Episode 53: Home Care Nursing for Patients With Cancer ONS Voice articles: Hazardous Drug Surface Contamination Prevails, Despite More Diligent PPE  NIOSH Releases Its 2024 List of Hazardous Drugs  No Place Like It: Home Care for Patients With Cancer  What Is ONS's Stance on Handling Chemotherapy While Pregnant, Breastfeeding, or Trying to Conceive?  What You Wear Matters When It Comes to Safety  ONS book: Safe Handling of Hazardous Drugs (Fourth Edition)  ONS course: Safe Handling Basics  Clinical Journal of Oncology Nursing article: Safe Management of Chemotherapy in the Home  ONS Learning Library: Safe Handling of Hazardous Drugs  ONS Position Statement: Ensuring Healthcare Worker Safety When Handling Hazardous Drugs  National Institute for Occupational Safety and Health article: Managing Hazardous Drug Exposures: Information for Healthcare Settings  NIOSH List of Hazardous Drugs in Healthcare Settings, 2024  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode  “So we look for a carcinogenic hazard. So does this molecule, does this chemical, this drug, have the ability to increase the risk of cancer? A lot of the time that will also tie with genotoxic hazards, but not always. There are some drugs on the list that are carcinogenic through other mechanisms. Sometimes carcinogenicity can be related to hormone signals, can lead to increased risk of cancer. There's some nuance there, but is it a carcinogenic hazard? That can get it onto the list. Is it a developmental and reproductive hazard?” TS 10:48  “NIOSH can't say what's right for every situation, but some organizations have suggested further precautions such as temporary alternative duty for workers who are pregnant or are looking to become pregnant. NIOSH can't say what's best for any given facility, but other organizations have given some good suggestions you may want to look into.” TS 13:18  “The list doesn't really rank hazard. I know a lot of people have kind of treated it that way a lot of times. We don't say that something is less hazardous if it's only a developmental or reproductive hazard, because if you're trying to have a child, then that's an important hazard to you. And we don't necessarily say something that's carcinogenic is more hazardous.” TS 14:34  “Some standard setting organizations have set standards for handling. Really in the oncology setting, particularly oncology pharmacy setting, it's really changed how some of the handling happens there because some of the standards come out of the pharmacy world. And what's happened there is some drugs that are oncology drugs, they might have been on table one before just because they were used in the treatment of cancer. They were antineoplastics, so they were on table one. Now, because they're not identified as a potential carcinogen and they don't have manufactured special handling information, they are now on table two.” TS 23:39  “Occasionally, if a drug comes out and has manufacturer special handling information, we'll go ahead and add it to the list. And since we won't add it into the publication, we typically have a table on that page that puts that there. If a drug is reevaluated and we find that the hazard is not as bad as expected or it's not a hazard, actually, and we can remove it from the list; sometimes we get new information and that happens.” TS 30:30 

Anti-aging technologies - with Dr. Mike Van Thielen! -Highlights from the AAD -Vitamin D for toxic erythema of chemotherapy -Updates on the skin microbiome -Join Luke's CME experience on Jak inhibitors! rushu.gathered.com/invite/ELe31Enb69Want to donate to the cause? Do so here!
Donate to the podcast: uofuhealth.org/dermasphere
Check out our video content on YouTube:
www.youtube.com/@dermaspherepodcast
and VuMedi!: www.vumedi.com/channel/dermasphere/
The University of Utah's Dermatology
ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -
⁠ Connect with us!
- Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC
- Instagram: dermaspherepodcast
- Facebook: www.facebook.com/DermaspherePodcast/
- Check out Luke and Michelle's other podcast,
SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our
friends at:
- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)
- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn
more dermatology!

In this episode with Peter Wilson we discuss the 13 calendar months, health, privacy, the corrupt officials and more #checkmatethematrix #matrix #peterwilsonAbout my Guest:Ex Royal Navy gunner and armourer, turned professional fighter. Owned and ran own martial arts gym for about 30 years. Always been aware of something not being right in the world, went deep into it after losing over £1million of property in 1 week including own home. So been up and been down even living in a car for a while with his wife Janine and 4 dogs. ---Awakening Podcast Social Media / Coaching My Other Podcasts  ⁠⁠⁠https://roycoughlan.com/⁠⁠ ------------------What we Discussed: 01:10 His Recent Event04:30 Oxygen Therapy07:20 Salt Therapy Room10:15 Water Vortex Machine13:35 Ozone Generator15:45 What was discussed about Crypto at the Event22:40 What is an Asset25:20 Gold and the French Warships going to the USA29:00 The FIAT Currency32:55 The 13 Month Calendar36:20 The Tides do not change41:40 Changing the Hrs twice yearly44:10 Protecting your Electronic Devices46:40 Cookies on the Internet49:15 There is No Privacy51:49 A lesson to Children about saying harsh words55:30 People are afraid to Support the People fighting the System57:30 People in Power Do Not Have Empathy1:00:15 City Officials treat you like Crap1:03:30 Is Your Job Helping Society or Hurting it1:03:50 GDPR to Help with Debt Collectors1:11:11 Holistic Dentistry1:18:04 Chemotherapy and Alternatives1:18:50 The Fog and how we can make change1:20:30 The Mouse in the Farmhouse StoryHow to Contact Peter:  https://www.claimyourstrawman.com/ https://checkmatethematrix.com/?linkId=lp_513119&sourceId=roy&tenantId=checkmate-the-matrixhttps://www.youtube.com/@ReturnToTrueDemocracy https://linktr.ee/PeterWilsonReturnToDemocracy https://www.linkedin.com/in/peter-wilson-a5a3872b/ ------------------------------All about Roy / Brain Gym & Virtual Assistants athttps://roycoughlan.com/------------------